Journal of Clinical and Experimental Ophthalmology
Open Access
ISSN: 2155-9570
ISSN: 2155-9570
Viral Kansara
Novartis Institutes for Biomedical Research, Inc., USA
Scientific Tracks Abstracts: J Clin Exp Ophthalmol
The field of sustained ocular drug delivey has seen remarkable innovations in the last decade. Many ocular blinding diseases require a chronic, in some cases lifelong treatment, and hence an unmet medical need for sustained ocular delivery technologies is becoming more evident. Recent advancements in novel drug delivery technologies have opened a new avenue in the field of sustained ophthalmic products. An integrative ocular drug delivery approach involvolving discovery scientists, pharmacologists, polymer chemists, clinicans, toxicologists and regulatory agenices is a paramount to the success of the sustained ocular delivery system. This talk will focus on key barriers and factors affecting ocular drug delivery, and strategies to overcome these barriers. Various routes of ocular drug administration and challenges associated with current strategies will be discussed in details. Key pharmacokinetic princiles and pharmacological considerations for developing successful sustained ocular delivery products will be presented. Recent advancements and future opportunities and a few success stories in the field of sustained drug delivery to the eye will also be discussed.
Viral Kansara is Investigator and Head of Ocular Pharmacology and Drug Delivery Laboratory in the Ophthalmology department at Novartis Institutes for Biomedical Research, Inc. He has over 10 years of combined industry and academia experience and expertise in the field of “Ocular drug discovery, delivery and drug development”. At Novartis, his lab focuses on “The discovery and development of novel treatment therapies” for blinding diseases such as macular degeneration, diabetic retinopathy and glaucoma.
Email: viral.kansara@novartis.com